|
1.
|
|
6 p, 377.9 KB |
Clinical and genetic differences between pustular psoriasis subtypes
/
Twelves, Sophie (King's College London) ;
Mostafa, Alshimaa (Beni Suef University) ;
Dand, Nick (King's College London) ;
Burri, Elias (University Hospital Zurich (Suïssa)) ;
Farkas, K. (University of Szeged) ;
Wilson, Rosemary (King's College London) ;
Cooper, Hywel L. (Portsmouth Hospitals Trust) ;
Irvine, Alan D. (Trinity College Dublin) ;
Oon, Hazel H. (National Skin Centre) ;
Kingo, Külli (Tartu University Hospital (Tartu, Estònia)) ;
Köks, Sulev (University of Tartu) ;
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Reynolds, Nick (Newcastle Hospitals NHS Foundation Trust) ;
Tan, Euegene Sern-Ting (National Skin Centre) ;
Tanew, Adrian (Medical University of Vienna) ;
Torz, Kaspar (Campus Kiel) ;
Trattner, Hannes (Medical University of Vienna) ;
Valentine, Mark (University of Washington School of Medicine) ;
Wahie, Shyamal (University Hospital of North Durham and Darlington Memorial Hospital) ;
Warren, Richard B. (University of Manchester and the Academic Health Science Centre) ;
Wright, Andrew (St University of Bradford) ;
Bata-Csörgő, Zsuzsa (University of Szeged) ;
Szell, Marta (University of Szeged) ;
Griffiths, Christopher E.M. (University of Manchester and the Academic Health Science Centre) ;
Burden, A.David (University of Glasgow) ;
Choon, Siew-Eng (Monash University Malaysia) ;
Smith, Catherine H. (King's College London) ;
Barker, Jonathan N. (King's College London) ;
Navarini, Alexander A. (University Hospital Zurich (Suïssa)) ;
Capon, Francesca (King's College London) ;
Universitat Autònoma de Barcelona
The term pustular psoriasis indicates a group of severe skin disorders characterized by eruptions of neutrophil-filled pustules. The disease, which often manifests with concurrent psoriasis vulgaris, can have an acute systemic (generalized pustular psoriasis [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua of Hallopeau [ACH]) presentation. [...]
2019 -  10.1016/j.jaci.2018.06.038
The Journal of Allergy and Clinical Immunology, Vol. 143 Núm. 3 (march 2019) , p. 1021-1026
|
|
|
2.
|
|
8 p, 509.9 KB |
Psoriasis and mental health workshop report : Exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk
/
Kleyn, C.Elise (Manchester Academic Health Science Centre) ;
Talbot, Peter S. (University of Manchester) ;
Mehta, Nehal N. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Sampogna, Francesca (IDI-IRCCS) ;
Bundy, Chris (Cardiff University) ;
Ashcroft, Darren M. (University of Manchester) ;
Kimball, Alexa B. (Beth Israel Deaconess Medical Center) ;
van de Kerkhof, Peter C.M. (International Psoriasis Council) ;
Griffiths, Christopher E.M. (NIHR Manchester Biomedical Research Centre) ;
Valenzuela, Fernando (University of Chile and Probity Medical Research) ;
van der Walt, Joelle M. (International Psoriasis Council) ;
Aberra, Tsion (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Puig-Verdié, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Psoriasis is a systemic, relapsing, inflammatory disease associated with serious comorbidities including mood problems and/or unhealthy lifestyle behaviours. Cutaneous and systemic abnormalities in innate and acquired immunity play a role in its pathogenesis. [...]
2020 - 10.2340/00015555-3375
Acta dermato-venereologica, Vol. 100 Núm. 1 (january 2020) , p. adv00020
|
|
|
3.
|
|
3 p, 1.3 MB |
Vaccine hesitancy and access to psoriasis care during the -19 pandemic : findings from a global patient-reported cross-sectional survey
/
Bechman, Katie (King's College London) ;
Cook, Emma S. (King's College London) ;
Dand, Nick (Health Data Research UK) ;
Yiu, Zenas Z.N. (The University of Manchester) ;
Tsakok, Teresa (King's College London) ;
Meynell, Freya (King's College London) ;
Coker, Bolaji (King's College London) ;
Vincent, Alexandra (King's College London) ;
Bachelez, Hervé (Université de Paris) ;
Barbosa, Ines (King's College London) ;
Brown, Matthew A. (King's College London) ;
Capon, Francesca (King's College London) ;
Contreras, Claudia R. (Universidad Nacional de Asuncion) ;
De La Cruz, Claudia (Clinica Dermacross) ;
Di Meglio, Paola (King's College London) ;
Gisondi, Paolo (University of Verona) ;
Jullien, Denis (Groupe de recherche sur le psoriasis (GrPso) de la Société Française de dermatologie) ;
Kelly, Jade (NIHR Manchester Biomedical Research Centre) ;
Lambert, Jo (Ghent University) ;
Lancelot, Camille (International Federation of Psoriasis Associations) ;
Langan, Sinead M. (London School of Hygiene and Tropical Medicine) ;
Mason, Kayleigh J. (Keele University) ;
McAteer, Helen (The Psoriasis Association) ;
Moorhead, Lucy (King's College London) ;
Naldi, Luigi (Centro Studi GISED) ;
Norton, Sam (King's College London) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Spuls, Phyllis I. (Amsterdam UMC. University Medical Center) ;
Torres, Tiago (Centro Hospitalar do Porto) ;
Urmston, Dominic (The Psoriasis Association) ;
Vesty, Amber (The Psoriasis Association) ;
Warren, Richard B. (NIHR Manchester Biomedical Research Centre) ;
Waweru, Hoseah (International Federation of Psoriasis Associations) ;
Weinman, John (King's College London) ;
Griffiths, Christopher E.M. (NIHR Manchester Biomedical Research Centre) ;
Barker, Jonathan (King's College London) ;
Smith, Catherine H. (King's College London) ;
Galloway, James B. (King's College London) ;
Mahil, Satveer K. (King's College London) ;
Universitat Autònoma de Barcelona
2022 - 10.1111/bjd.21042
British journal of dermatology, Vol. 187 (may 2022) , p. 254-256
|
|
|
4.
|
|
18 p, 504.6 KB |
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure
/
Armstrong, April W (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ;
Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Boehncke, Wolf-Henning (University of Geneva. Department of Pathology and Immunology) ;
Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ;
Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ;
Papp, Kim (K Papp Clinical Research and Probity Medical Research) ;
Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ;
Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ;
Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ;
Renda, Lisa (Eli Lilly and Company) ;
Agada, Noah (Eli Lilly and Company) ;
Xu, Wen (Eli Lilly and Company) ;
Gallo, Gaia (Eli Lilly and Company) ;
Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ;
Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150
|
|
|
5.
|
|
1 p, 320.3 KB |
Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
/
Blauvelt, Andrew (SW Locust St., Suite G, Portland, OR 97223 USA) ;
Papp, Kim A. (Waterloo, Canada) ;
Griffiths, Christopher E. M. (Manchester, UK) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ;
Dutronc, Yves (Indianapolis, IN USA) ;
Kerr, Lisa Farmer (Indianapolis, IN USA) ;
Ilo, Dapo (Indianapolis, IN USA) ;
Mallbris, Lotus (Indianapolis, IN USA) ;
Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ;
Universitat Autònoma de Barcelona
2018 - 10.1007/s40257-018-0353-x
American Journal of Clinical Dermatology, Vol. 19 (march 2018) , p. 457
|
|
|
6.
|
|
8 p, 420.3 KB |
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders : a Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
/
Blauvelt, Andrew (SW Locust St., Suite G, Portland, USA) ;
Papp, Kim A. (Waterloo, Canada) ;
Griffiths, Christopher E. M. (Manchester, UK) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ;
Dutronc, Yves (Indianapolis, IN USA) ;
Kerr, Lisa Farmer (Indianapolis, IN USA) ;
Ilo, Dapo (Indianapolis, IN USA) ;
Mallbris, Lotus (Indianapolis, IN USA) ;
Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ;
Universitat Autònoma de Barcelona
Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. [...]
2017 - 10.1007/s40257-016-0246-9
American Journal of Clinical Dermatology, Vol. 18 (january 2017) , p. 273-280
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
